We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
-10.52%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$314M
AUM Growth
-$86.9M
Cap. Flow
-$24.2M
Cap. Flow %
-7.71%
Top 10 Hldgs %
50.55%
Holding
86
New
32
Increased
12
Reduced
15
Closed
25

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$18.5M
2
SRRK icon
Scholar Rock
SRRK
+$15.4M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$13.5M
4
QURE icon
uniQure
QURE
+$8.99M
5
CGON icon
CG Oncology
CGON
+$8.15M

Top Sells

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$18M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$16.2M
3
INCY icon
Incyte
INCY
+$13.4M
4
MRUS
Merus
MRUS
+$11.7M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.31%
2 Financials 0.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TARA icon
26
Protara Therapeutics
TARA
$230M
$5.07M 1.62%
1,190,579
+858,185
+258% +$3.83M
KALV
27
DELISTED
KalVista Pharmaceuticals
KALV
$4.46M 1.42%
386,837
-605,966
-61% -$6.18M
EWTX icon
28
Edgewise Therapeutics
EWTX
$4.28B
$3.97M 1.26%
180,255
+47,549
+36% +$1.25M
SRZN icon
29
Surrozen
SRZN
$255M
$2.81M 0.9%
240,826
-109,747
-31% -$1.28M
PTGX icon
30
Protagonist Therapeutics
PTGX
$9.06B
$2.38M 0.76%
49,241
-92,473
-65% -$3.87M
ELVN icon
31
Enliven Therapeutics
ELVN
$3.8B
$2.37M 0.76%
120,430
+23,714
+25% +$510K
NBIX icon
32
Neurocrine Biosciences
NBIX
$17.2B
$2.33M 0.74%
+21,052
New +$2.67M
ASND icon
33
Ascendis Pharma A/S
ASND
$17.1B
$2.3M 0.73%
+14,732
New +$2.1M
BBOT
34
BridgeBio Oncology
BBOT
$686M
$2.27M 0.72%
200,900
– –
SYRE icon
35
Spyre Therapeutics
SYRE
$8.7B
$2.2M 0.7%
+136,139
New +$2.83M
FOLD
36
DELISTED
Amicus Therapeutics
FOLD
$2.19M 0.7%
+268,919
New +$2.49M
NAMS icon
37
NewAmsterdam Pharma
NAMS
$3.7B
$2.14M 0.68%
+104,585
New +$2.32M
RYTM icon
38
Rhythm Pharmaceuticals
RYTM
$7.31B
$1.79M 0.57%
33,816
-174,200
-84% -$9.66M
ABUS icon
39
Arbutus Biopharma
ABUS
$901M
$1.63M 0.52%
+467,882
New +$1.56M
PCSC
40
Perceptive Capital Solutions
PCSC
$123M
$1.54M 0.49%
150,000
– –
GERN icon
41
Geron
GERN
$924M
$1.53M 0.49%
+960,307
New +$2.34M
IDYA icon
42
IDEAYA Biosciences
IDYA
$3.47B
$1.1M 0.35%
+66,999
New +$1.43M
ZLAB icon
43
Zai Lab
ZLAB
$2.28B
$955K 0.3%
+26,421
New +$813K
OCUL icon
44
Ocular Therapeutix
OCUL
$1.96B
$913K 0.29%
+124,523
New +$957K
DYN icon
45
Dyne Therapeutics
DYN
$3.92B
$883K 0.28%
+84,430
New +$1.21M
SLNO
46
DELISTED
Soleno Therapeutics
SLNO
$797K 0.25%
+11,155
New +$543K
IFRX icon
47
InflaRx
IFRX
$272M
$740K 0.24%
+725,019
New +$1.37M
SLDB icon
48
Solid Biosciences
SLDB
$858M
$733K 0.23%
+198,150
New +$848K
WVE icon
49
Wave Life Sciences
WVE
$1.12B
$726K 0.23%
89,833
-631,376
-88% -$6.9M
MBX
50
MBX Biosciences
MBX
$2.99B
$713K 0.23%
+96,615
New +$1.02M
1
2
3 4

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q1 2025 Portfolio in Review

As of Q1 2025, Stempoint Capital held 86 positions worth $314M, down 22% from $401M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Stempoint Capital withdrew a net $24.2M in Q1 2025, closing 25 positions and reducing 15 holdings. Its most notable exit was Crinetics Pharmaceuticals, an estimated $16.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

Against the trend, Stempoint Capital opened a new position in Arcellx worth $18M.

  • Stempoint Capital's largest Q1 2025 buy was Arcellx: 273,774 shares worth $18M.
  • Stempoint Capital added most to Scholar Rock in Q1 2025, an estimated $15.4M increase.
  • Stempoint Capital's biggest Q1 2025 reduction was Syndax Pharmaceuticals, cutting an estimated $18M.
  • Stempoint Capital fully exited Crinetics Pharmaceuticals in Q1 2025, selling an estimated $16.2M.
  • Stempoint Capital's ten largest holdings make up 51% of its $314M portfolio in Q1 2025.
  • Stempoint Capital opened 32 new positions and closed 25 in Q1 2025.
  • Stempoint Capital's portfolio value fell 22% quarter-over-quarter to $314M.

Based on Stempoint Capital's 13F filing for Q1 2025, filed 15 May 2025.